1.402 articles found

Serum LncRNA XIST and miR-133b as non-invasive biomarkers for diagnosis and progression of Parkinson's disease.

Rao W, Qin Y.

J Neurogenet · 2025-12-06

DOI: 10.1080/01677063.2025.2591630PMID: 41351434

UBC9 mediates mitophagy to attenuate oxidative stress by regulating SUMOylation of PINK1 in the Parkinson's disease progression.

Liu J, Jia G, Zhou Y, Zhang J, Wang Y, Cai Y.

Cell Biol Toxicol · 2025-12-06

DOI: 10.1007/s10565-025-10126-3PMID: 41351721

The role of the gut microbiome in the progression of Parkinson's disease: a systematic review of patient cohorts.

Peters M, Hegelmaier T, Wegner F, Höllerhage M, Ye L, Niesmann C, Schneidereit IV, Haghikia A, Klietz M.

J Neurol · 2025-12-06

DOI: 10.1007/s00415-025-13545-8PMID: 41351765

Profiling the Braak progression in Parkinson's disease: a transcriptomics and ML driven identification of progressive biomarker and prognostic ceRNA signature.

Sarkar S, Podder S.

Neuroscience · 2025-12-06

DOI: 10.1016/j.neuroscience.2025.12.011PMID: 41360364

Understanding the pattern of cognitive decline in GBA1-related Parkinson’s Disease: a longitudinal multi-cohort study

Bode M, Pauly C, Jónsdóttir SR, Schulte C, Becker S, Wurster I, Roeben B, Lerche S, Poewe W, Krüger R, Liepelt-Scarfone I, Brockmann K, the Parkinson’s Progression Markers Initiative*.

· 2025-12-02

DOI: 10.64898/2025.12.01.25341351

Plasma Synuclein Aggregate Detection via Constant Shake‐Induced Conversion: A Novel Biomarker for Parkinson's Disease Diagnosis and Progression

Ryoo N, Ko H.

Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025-12-01

Gray and white matter pathology progression in Parkinson's disease patients that develop mild cognitive impairment

Moqadam R, Azizi H, Zeighami Y, Dadar M.

Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025-12-01

Author Correction: A blood-based DNA damage signature in patients with Parkinson's disease is associated with disease progression.

Sproviero D, Payán-Gómez C, Milanese C, Barnhoorn S, Sun S, Gyenis A, Delia D, Lashley T, Hoeijmakers JHJ, Vijg J, Mastroberardino PG.

Nat Aging · 2025-12-01

DOI: 10.1038/s43587-025-01037-3PMID: 41258491

Alpinetin Targets Mitophagy Pathways to Mitigate Parkinson's Disease Progression.

Shen Z, Shan X, Zhang S, Huang D, Hu H, Liang Y, Zhu H, Zhang L, Chen Y.

CNS Neurosci Ther · 2025-12-01

DOI: 10.1002/cns.70676PMID: 41331739

PDualNet: a deep learning framework for joint prediction of Parkinson's disease progression subtype and MDS-UPDRS scores.

Rizou V, Grammalidis N, Daras P, Dimitropoulos K.

Sci Rep · 2025-11-25

DOI: 10.1038/s41598-025-25812-9PMID: 41290857

Sex similarities and differences in cognition: A longitudinal study of healthy control participants from the Parkinson Progression Markers Initiative.

Ohlhauser L, Kwan H, Casey H, MacDonald S, Gawryluk JR.

PLoS One · 2025-11-24

DOI: 10.1371/journal.pone.0334358PMID: 41284664

Early deep brain stimulation attenuates parkinsonism progression in a neurotoxin-induced Parkinson's disease mouse model.

Merino-Ruiz MC, Goulart JT, Penha GDS, de Santana IA, Mortari MR.

Exp Neurol · 2025-11-22

DOI: 10.1016/j.expneurol.2025.115567PMID: 41285281